# Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

Study · id `cardio:ct-nct07173712` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07173712](<https://clinicaltrials.gov/study/NCT07173712>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07173712

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 324 participants.

## Technical summary

Registry record NCT07173712. Randomized; no masking; primary purpose treatment. Start 2026-03-15 (anticipated); primary completion 2027-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 324 participants (planned count; ClinicalTrials.gov record NCT07173712, source copy `cardio:ctgov-nct07173712-2026-02-06`, retrieved 2026-10-26)
- Planned start: 2026-03-15 (anticipated) (ClinicalTrials.gov record NCT07173712, source copy `cardio:ctgov-nct07173712-2026-02-06`, retrieved 2026-10-26)
- Primary completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07173712, source copy `cardio:ctgov-nct07173712-2026-02-06`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07173712, source copy `cardio:ctgov-nct07173712-2026-02-06`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07173712-2026-02-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): CSII
- Intervention (Drug): Insulin glargine /lixisenatide Fixed Ratio Combination
- Intervention (Drug): Insulin Degludec and Insulin Aspart Injection
- Intervention (Drug): Insulin Glargine (HOE901 - U300)
- Intervention (Drug): Metformin
- Lead sponsor: Yanbing Li
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: fb4900523ac912fd8f033ce54334af0119279d232ddf6ba419497a908b8ec96d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
